Stage III Pancreatic Cancer Clinical Trial
Official title:
A Phase I Study of OSI-774 in Combination With Gemcitabine and Radiation in Locally Advanced, Non-Operable Pancreatic Cancer
Verified date | June 2013 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This phase I trial is studying the side effects and best dose of erlotinib when given together with gemcitabine and radiation therapy in treating patients with locally advanced unresectable pancreatic cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining erlotinib with gemcitabine may make the tumor cells more sensitive to radiation therapy and may kill more tumor cells.
Status | Completed |
Enrollment | 28 |
Est. completion date | |
Est. primary completion date | February 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed adenocarcinoma of the pancreas - Locally advanced, unresectable disease, defined by all of the following: - Obvious encasement of the celiac, hepatic, or superior mesenteric artery - Encasement of the portal or superior mesenteric vein not amenable to surgical resection - Extrapancreatic extension with or without regional lymph node involvement - No evidence of distant metastatic disease by staging laparoscopy* - Locally recurrent disease after prior curative surgery allowed provided the following are true: - No prior chemotherapy or radiotherapy - No evidence of distant metastatic disease by staging laparoscopy* - No islet cell pancreatic cancer or lymphoma or sarcoma of the pancreas - Measurable or evaluable disease - Primary pancreatic tumor is considered evaluable and not measurable disease - Lymph node mass considered measurable disease - No known brain metastases - Performance status - ECOG 0-2 - More than 12 weeks - WBC = 3,000/mm^3 - Absolute neutrophil count = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Bilirubin = 1.5 mg/dL - AST and ALT = 2.5 times upper limit of normal - Creatinine = 2.0 mg/dL - Creatinine clearance = 60 mL/min - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia - No abnormalities of the cornea based on history (e.g., dry eye syndrome or Sjögren's syndrome) - No congenital abnormality (e.g., Fuch's dystrophy) - No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose) - No abnormal corneal sensitivity test (Schirmer test or similar tear production test) - No Crohn's disease or inflammatory bowel disease that would preclude undergoing external beam radiotherapy - Able to tolerate oral medication - No requirement for IV alimentation - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No ongoing or active infection - No other concurrent uncontrolled illness - No psychiatric illness or social situation that would preclude study compliance - See Disease Characteristics - No prior gemcitabine - See Disease Characteristics - See Disease Characteristics - No prior epidermal growth factor receptor-targeting therapy - No prior therapy for pancreatic cancer (except surgery) - No concurrent commercial or other investigational agents or therapies intended to treat the malignancy - No concurrent combination antiretroviral therapy for HIV-positive patients |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan-Kettering Cancer Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum-tolerated dose (MTD) of erlotinib hydrochloride based on the incidence of dose-limiting toxicity (DLT) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 | 7.5 weeks | Yes | |
Secondary | Toxicity as assessed by CTCAE version 3.0 | 7.5 weeks | Yes | |
Secondary | Response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) | Kaplan-Meier methods will be utilized to estimate the response duration. | Up to 6 years | No |
Secondary | Progression-free survival as assessed by RECIST | Kaplan-Meier methods will be utilized to estimate the progression-free survival. | From the time of study enrollment until progression of disease is documented, assessed up to 6 years | No |
Secondary | Overall survival | From the time of study enrollment until the date of death, assessed up to 6 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01959672 -
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT02345460 -
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
|
Phase 2 | |
Completed |
NCT00095966 -
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00020345 -
Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas
|
Phase 2 | |
Completed |
NCT02897375 -
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT02896907 -
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT01068327 -
Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT02307539 -
Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer
|
N/A | |
Completed |
NCT01222689 -
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00026104 -
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03899649 -
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
|
||
Completed |
NCT01821612 -
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer
|
Early Phase 1 | |
Terminated |
NCT01739439 -
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
|
Phase 1 | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00323583 -
Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
|
Phase 2 | |
Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A |